Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Teriparatide to Denosumab Switch Helpful in Osteoporosis

David Douglas  |  July 16, 2015

NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…

On Research Review Boards, Conflict-of-Interest Reporting Improves

Kathryn Doyle  |  July 16, 2015

(Reuters Health)—Many doctors who serve on hospital panels overseeing the ethics and safety of human research trials have industry relationships that may compromise their objectivity, but reporting these conflicts has become more common over the past 10 years, according to a new study. Physicians who serve on so-called institutional review boards (IRBs) may also be…

Greece Bans Export of 25 Drugs after Pharmacists’ Supply Warnings

Lefteris Karagiannopoulos  |  July 15, 2015

ATHENS (Reuters)—Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings by pharmacists that they faced difficulties in securing some supplies. A ministry spokeswoman said the Greek drugs regulator had told a meeting at the ministry on Friday—when the pharmacists made their warnings—that there had…

Secukinumab Effective for Treating Psoriatic Arthritis

Reuters Staff  |  July 15, 2015

NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…

U.S. House Passes Bill to Speed New Drugs to Market

Reuters Staff  |  July 15, 2015

WASHINGTON (Reuters)—The U.S. House of Representatives on Friday passed a bill aimed at speeding new drugs to the market after lawmakers defeated last-minute amendments that threatened to derail it. The House voted 344 to 77 in favor of the bill, known as the 21st Century Cures Act, which would require the FDA to streamline the…

FDA Strengthens Warning Label for Certain Antiinflammatory Drugs

Reuters Staff  |  July 14, 2015

(Reuters)—The U.S. Food and Drug Administration is strengthening an existing warning label that non-aspirin, non-steroidal antiinflammatory drugs (NSAIDs) increase the risk of heart attack or stroke. NSAIDs include ibuprofen, naproxen, diclofenac and celecoxib, all of which carry FDA warning labels. The agency said it would require updates to the labels of prescription and over-the-counter (OTC)…

CMS Acts on the ACR’s Requests & Announces ICD-10 Grace Period

Will Harvey  |  July 14, 2015

In a win for the ACR and rheumatologists, for one year after the mandatory ICD-10 implementation on Oct. 1, 2015, CMS will not deny claims on the basis of incorrect ICD-10 sub-codes.

White House Is Open to Working with Congress on Disease Research Bill

Reuters Staff  |  July 13, 2015

WASHINGTON (Reuters)—The White House said on Wednesday it was open to working with Congress on a bill that would invest in disease research and would be paid for with sales of oil from U.S. emergency reserves. The House of Representatives is considering a bipartisan bill that would increase funding for the U.S. National Institutes of…

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman  |  July 10, 2015

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…

Knee Surgery for Pain May Not Be Worthwhile

Lisa Rapaport  |  July 9, 2015

(Reuters Health)—Middle-aged and older adults with torn cartilage or painful arthritis in their knee are not likely to benefit from arthroscopic surgery, and could be harmed by it, a review of past studies hints. Researchers reviewed nine previous studies with a combined 1,270 patients and found the surgery no better than other options like exercise…

  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences